Tron Pharmaceuticals, Inc. formerly Nanopharmaceutics, Inc., is a clinical-stage specialty pharmaceutical company. The Company is developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. It is developing a clinical pipeline of oral, topical and injectable small molecule drug candidates to treat human cancer, central nervous system (CNS) disorders and infectious diseases. Its pipeline includes 10 clinical-stage proprietary and partnered programs including Triapine, Ammonium Tetrathiomolybdate and Aza-TdC, targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3, targeting CNS; and Ramoplanin and NanoDOX, targeting infectious disease. Leveraging its expertise in nanoparticle and fine-particle formulations, the Company is focused on formulation development aimed at improving drug absorption and stability. Its Triapine is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity.